Shawbrook
HealthInvestor  Barometer Survey 2014
 
 
Remember me:
Skip Navigation Links
Axis-Shield resists new Alere takeover attempt

UK-based diagnostics company Axis-Shield has urged shareholders to resist a fresh takeover attempt by US rival Alere.

In a statement today, Alere repeated its offer to Axis-Shield’s shareholders of 460 pence per share, which was formally made on 5 August. The offer, rejected by the Axis-Shield board, values the business at £230 million.

Alere announced today that it is lowering the threshold of its bid, which had been set at 90% of shareholder acceptance. The company said it now required more than 50% of voting rights, giving it the option of becoming a majority shareholder in Axis-Shield.

The US company also warned that if its offer were to lapse by a deadline of 10 October, “there is a strong possibility that Axis-Shield's share price would fall significantly below its current share price, particularly as no other potential bidder has announced its interest publicly”.

Alere said it was also looking at “alternative acquisitions, particularly in light of current valuations and market conditions”, and that it didn’t necessarily have to acquire Axis-Shield in order to achieve its “strategic objectives”.

In response, Axis-Shield’s board said it was “disappointed” that Alere had not taken notice of the “firm rebuttal” from shareholders to its offer, which it said was clear by the less than 1% level of acceptances that was disclosed in an Alere announcement on 16 September.

“The board has been more than willing to engage with Alere if Alere were to put a proposal to the board that fairly reflected the fundamental value of Axis-Shield. To date, no such proposal has been received from Alere,” said an Axis-Shield statement.

“The company has made excellent progress in the first half of the year and is on track to deliver for the second half of the year. The company believes that Alere is making a highly opportunistic offer in order to try and acquire Axis-Shield on the cheap.”

The 460 pence per share offer price represents a premium of 37% on the closing share price of 335 pence on 5 July 2011 – the last business day before Alere revealed it was considering an approach.
 

Posted on: 26/09/2011

Latest news stories

18/12/2014
Waterland Private Equity Investments has decided to merge its two German healthcare portfolio companies Median Kliniken and RHM Group into one acute care and rehabilitation group.
18/12/2014
NHS England has announced that it will allocate £1.1 billion of the £2 billion George Osborne pledged for 2015-16 to underfunded clinical commissioning groups.
18/12/2014
A government children’s social care services programme has financially backed its first four projects as its total funds increased to £100 million in value.
16/12/2014
According to the Regus Business Confidence index, 61% of British healthcare firms have seen profits rise in 2014 compared to last year.
15/12/2014
Torbay & South Devon NHS Trust has named Mears Group the preferred bidder to run its Living Well@Home Services contract.


HealthInvestor looks back on 2014 and highlights the defining moments for the sector
Read more...
The number of people buying into private healthcare has remained largely flat. Can this change if prices are pushed down, as Bupa claims? Ploy Radford investigates
Read more...
Although Britain has seen two successful healthcare IPOs this year, much of the action has been in Australia and the Middle East.
Read more...
HealthInvestor looks back on 2014 and highlights the defining moments for the sector
Candesic’s Marc Kitten and Dr Joe Taylor explore how existing software platforms and technologies could address healthcare’s looming workforce crisis
MedicX and the healthcare division at Octopus Investments have joined forces to create Octopus Healthcare. Sunniva Davies-Rommetveit spoke to Mike Adams and Shay Ramalingam about their grand plans for the future
Sunniva Davies-Rommetveit asks whether Simon Stevens’ ‘Five year forward view’ encapsulates his own saying “think like a patient, act like a taxpayer”, or if significant issues are left unaddressed
Although Britain has seen two successful healthcare IPOs this year, much of the action has been in Australia and the Middle East. Adrian Murdoch reports

Click here to search all feature articles